Tweet
Eur J Neurol. 2017 Dec 4. doi: 10.1111/ene.13537. [Epub ahead of print]
Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy.
Olberg HK1,2, Eide GE3,4, Cox RJ5,6,7, Jul-Larsen ?6,7, Lartey SL5,6,7, Vedeler CA1,2,8, Myhr KM9,8.
Author information
Abstract
BACKGROUND:
We have previously shown that multiple sclerosis patients receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization.
OBJECTIVES:
To further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls.
METHODS:
Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared to 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre- and three, six and 12 months post-vaccination. The vaccine responses were evaluated by the haemagglutination inhibition assay and adjusted for age and gender.
RESULTS:
No significant differences in rates of protection against H1N1 for interferon beta-1a/1b and glatiramer acetate were observed as compared to controls at three, six and 12 months. Fingolimod provided reduced protection at all time points post-vaccination while natalizumab displayed reduced protection at three and six months. Patients without immunomodulation did not display significantly different protection rates as the controls at three and 12 months.
CONCLUSION:
These findings suggest that MS patients receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza-specific vaccine responses. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Immunomodulation; Immunotherapy; Protection; multiple sclerosis; seasonal influenza vaccination
PMID: 29205701 DOI: 10.1111/ene.13537
Antibody response to seasonal influenza vaccination in multiple sclerosis patients receiving immunomodulatory therapy.
Olberg HK1,2, Eide GE3,4, Cox RJ5,6,7, Jul-Larsen ?6,7, Lartey SL5,6,7, Vedeler CA1,2,8, Myhr KM9,8.
Author information
Abstract
BACKGROUND:
We have previously shown that multiple sclerosis patients receiving immunomodulatory treatment have reduced seroprotection rates after influenza immunization.
OBJECTIVES:
To further investigate the influence of immunomodulatory therapies on the antibody response and seroprotection rates in patients immunized with seasonal influenza vaccine in 2012/2013 compared to healthy controls.
METHODS:
Ninety patients receiving fingolimod, glatiramer acetate, interferon beta-1a/1b, natalizumab or no therapy were compared to 62 healthy controls. All subjects received the inactivated split virus vaccine in 2012 and serum samples were collected pre- and three, six and 12 months post-vaccination. The vaccine responses were evaluated by the haemagglutination inhibition assay and adjusted for age and gender.
RESULTS:
No significant differences in rates of protection against H1N1 for interferon beta-1a/1b and glatiramer acetate were observed as compared to controls at three, six and 12 months. Fingolimod provided reduced protection at all time points post-vaccination while natalizumab displayed reduced protection at three and six months. Patients without immunomodulation did not display significantly different protection rates as the controls at three and 12 months.
CONCLUSION:
These findings suggest that MS patients receiving fingolimod or natalizumab should be considered for a second dose of the vaccine in cases of insufficient protection. Our results further indicate that new immunomodulatory treatment regimens should be systematically evaluated for their influence on influenza-specific vaccine responses. This article is protected by copyright. All rights reserved.
This article is protected by copyright. All rights reserved.
KEYWORDS:
Immunomodulation; Immunotherapy; Protection; multiple sclerosis; seasonal influenza vaccination
PMID: 29205701 DOI: 10.1111/ene.13537